High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption

被引:1
|
作者
Drouin-Chartier, Jean-Philippe [1 ,2 ,3 ]
Tremblay, Andre J. [1 ]
Bergeron, Jean [2 ,3 ]
Lamarche, Benoit [4 ]
Couture, Patrick [1 ,2 ,3 ]
机构
[1] Laval Univ, Dept Med, Inst Nutr & Funct Foods, Quebec City, PQ, Canada
[2] Laval Univ, CHU Quebec, Dept Med, Lipid Clin, Quebec City, PQ, Canada
[3] Laval Univ, CHU Quebec, Dept Med, Lipid Res Ctr, Quebec City, PQ, Canada
[4] Laval Univ, Sch Nutr, Inst Nutr & Funct Foods, Quebec City, PQ, Canada
基金
加拿大健康研究院; 加拿大自然科学与工程研究理事会;
关键词
Homozygous familial hypercholesterolemia; Lipoprotein apheresis; Dextran sulfate adsorption; Triglyceride; LDL-Cholesterol; CORONARY-HEART-DISEASE; LDL RECEPTOR GENE; CARDIOVASCULAR-DISEASE; FRIEDEWALD FORMULA; CHOLESTEROL; PLASMA; MUTATION; HYPERLIPOPROTEINEMIA; APOLIPOPROTEIN(A); POPULATION;
D O I
10.1016/j.atherosclerosis.2018.01.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: Maximizing the acute reduction of LDL-cholesterol (C) and lipoprotein (a) (Lp(a)) concentrations in patients with homozygous familial hypercholesterolemia (HoFH) is the main goal of lipoprotein apheresis (LA). The objective of this study was to examine how the pre-LA serum TG concentrations influence the efficacy of LA to acutely reduce LDL-C and Lp(a) concentrations in HoFH patients. Methods: Data from 1761 LA treatments of HoFH patients (n = 10) and compound heterozygous patients (n = 5) collected between 2008 and 2016 were analyzed. These data included the pre-and post-LA concentrations of LDL-C, TGs and Lp(a); volume of filtered plasma; type of LA system used (dextran sulfate adsorption (DSA) or heparin-induced extracorporeal LDL precipitation (HELP)); and interval between treatments. Results: A significant association between the pre-LA TG concentrations and acute LA-induced reduction in LDL-C, modified by the type of LA system used, was observed (p pre-LA TG quartile*LA system =.04). Using the DSA system, the acute reduction of the LDL-C concentrations was attenuated by 3.9% when the preLA TG concentrations were > 2.09 mmol/L vs. <= 0.93 mmol/L (highest vs. lowest quartiles: =59.4% vs. =63.3%, p =.007). Using the HELP system, no significant difference was observed in the reduction of LDL-C between the highest and the lowest quartiles of serum TGs (=65.8% vs. =66.4%, p =.9). No association was observed between pre-LA TG concentrations and acute LA-induced decrease in Lp(a) (p =.2). Conclusions: The efficacy of LA is inversely associated with pre-LA TG concentrations in HoFH patients who used the DSA system instead of the HELP system. (c) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:26 / 32
页数:7
相关论文
共 50 条
  • [41] Efficacy of Evolocumab vs low-density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01)
    Torres, Esther
    Goicoechea, Marian
    Hernandez, Andres
    Rodriguez Ferrero, Maria L.
    Garcia, Ana
    Macias, Nicolas
    Anaya, Fernando
    JOURNAL OF CLINICAL APHERESIS, 2020, 35 (01) : 9 - 17
  • [42] Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles
    Hovland, Anders
    Marcovina, Santica
    Hardersen, Randolf
    Enebakk, Terje
    Mollnes, Tom Eirik
    Lappegard, Knut Tore
    TRANSFUSION AND APHERESIS SCIENCE, 2012, 46 (01) : 73 - 76
  • [43] Lipoprotein apheresis: an established therapeutic modality for homozygous familial hypercholesterolemia patients refractory to PCSK9 inhibitors: a case report and literature review
    Guan, Mingjing
    Wang, Hao
    Wang, Fang
    Liang, Shichu
    Ling, Li
    Wang, Bo
    Zhang, Ling
    THROMBOSIS JOURNAL, 2024, 22 (01):
  • [44] Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and Lipoprotein apheresis
    Stefanutti, Claudia
    Morozzi, Claudia
    Di Giacomo, Serafina
    Sovrano, Barbara
    Mesce, Dario
    Grossi, Alberto
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (04) : 782 - 789
  • [45] The Low-Density Lipoprotein Receptor Genotype Is a Significant Determinant of the Rebound in Low-Density Lipoprotein Cholesterol Concentration After Lipoprotein Apheresis Among Patients With Homozygous Familial Hypercholesterolemia
    Drouin-Chartier, Jean-Philippe
    Tremblay, Andre J.
    Bergeron, Jean
    Lamarche, Benoit
    Couture, Patrick
    CIRCULATION, 2017, 136 (09) : 880 - 882
  • [46] Elevated serum MMP-9/TIMP-1 ratio in patients with homozygous familial hypercholesterolemia Effects of LDL-apheresis
    Nenseter, Marit S.
    Narverud, Ingunn
    Graesdal, Asgeir
    Bogsrud, Martin P.
    Halvorsen, Bente
    Ose, Leiv
    Aukrust, Pal
    Holven, Kirsten B.
    CYTOKINE, 2013, 61 (01) : 194 - 198
  • [47] Cardiovascular Outcome of Pediatric Patients With Bi- Allelic (Homozygous) Familial Hypercholesterolemia Before and After Initiation of Multimodal Lipid Lowering Therapy Including Lipoprotein Apheresis
    Taylan, Christina
    Driemeyer, Joenna
    Schmitt, Claus P.
    Pape, Lars
    Buescher, Rainer
    Galiano, Matthias
    Koenig, Jens
    Schuerfeld, Carsten
    Spitthoever, Ralf
    Versen, Axel
    Koziolek, Michael
    Marsen, Tobias A.
    Stein, Holger
    Schaefer, Juergen R.
    Heibges, Andreas
    Klingel, Reinhard
    Oh, Jun
    Weber, Lutz T.
    Klaus, Gunter
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 136 : 38 - 48
  • [48] Familial Combined Hyperlipidemia (FCH) Patients with High Triglyceride Levels Present with Worse Lipoprotein Function Than FCH Patients with Isolated Hypercholesterolemia
    Puig, Nuria
    Minambres, Inka
    Benitez, Sonia
    Gil, Pedro
    Grau-Agramunt, Margarida
    Rivas-Urbina, Andrea
    Perez, Antonio
    Luis Sanchez-Quesada, Jose
    BIOMEDICINES, 2020, 8 (01)
  • [49] Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab
    Thedrez, Aurelie
    Blom, Dirk J.
    Ramin-Mangata, Stephane
    Blanchard, Valentin
    Croyal, Mikael
    Chemello, Kevin
    Nativel, Brice
    Pichelin, Matthieu
    Cariou, Bertrand
    Bourane, Steeve
    Tang, Lihua
    Farnier, Michel
    Raal, Frederick J.
    Lambert, Gilles
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (03) : 592 - 598
  • [50] LDL-apheresis by lipid filtration in patients with severe hypercholesterolemia and coronary heart disease: Effect of two different anticoagulation methods and comparison with dextran sulfate adsorption
    Geiss, H
    Otto, C
    Empen, K
    Peetz, D
    Klingel, R
    Parhofer, K
    ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (01) : 120 - 120